Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Goldman Sachs Says Buy 4 Biotech Stocks in Front of Q1 Earnings
07:15am, Monday, 27'th Apr 2020
In what has become truly the most challenging investing environment in decades, it is probably no surprise to most investors that health care is the top-performing sector this year in the S&P 500.
7 Beautiful Biotech Stocks to Buy Here
11:41am, Friday, 24'th Apr 2020
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre
09:57am, Monday, 20'th Apr 2020
Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
Nasdaq Caps Big Weekly Gain, S&P 500 Passes Key Test
05:03pm, Friday, 17'th Apr 2020
The S&P 500 gapped up Friday and reclaimed its 50-day moving average.
Incyte, Novartis launch drug study to treat coronavirus complication
04:49pm, Friday, 17'th Apr 2020
Incyte Corp. INCY, +4.53% said Friday it and Novartis AG NVS, +1.99% started a late-stage clinical trial to study a drug meant to treat a serious complication of COVID-19.
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
10:51am, Friday, 03'rd Apr 2020
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
09:48am, Friday, 03'rd Apr 2020
Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
08:38pm, Thursday, 02'nd Apr 2020
Both diseases involve an overactive immune system.
10 Stocks To Buy With Low Debt And High Liquidity
08:15am, Friday, 27'th Mar 2020
Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather
Incyte (INCY) Down 5.4% Since Last Earnings Report: Can It Rebound?
11:30am, Saturday, 14'th Mar 2020
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating
03:12pm, Tuesday, 10'th Mar 2020
On Tuesday, Incyte got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.
The post Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on Investor's Busine
These 2 Things Will Help Incyte’s Stock Rebound
10:00am, Wednesday, 04'th Mar 2020
Here's why Incyte could recover from its poor performance in recent weeks.
Incyte A Buy On 2020 Guidance And Possible Drug Approvals
03:48pm, Wednesday, 19'th Feb 2020
Incyte A Buy On 2020 Guidance And Possible Drug Approvals
Incyte's Ruxolitinib Works in Patients With Eczema
12:37pm, Wednesday, 19'th Feb 2020
The biotech company just reported data from a pair of successful late-stage clinical trials.
Better Buy: Vertex Pharmaceuticals vs. Incyte
11:45am, Wednesday, 19'th Feb 2020
Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.
